MyHealthChecked (M3HC) & Alliance (APH): Are these pharma stocks a buy now?

2 min read | September 30, 2021 04:55 PM AEST | By Nidhi Gupta

Highlights 

  • MyHealthChecked had recently acquired Nell Health Ltd, a technology-led genetic-testing platform and provider of personalised nutrition solutions, for £1.2 million.
  • Alliance Pharma declared an interim dividend of 0.563 pence per share, representing an increase of 5% year-on-year.

AIM-listed pharma companies include players that are engaged in developing various drugs, diagnostics, and technologies. Several of the AIM pharma companies have shifted focus entirely or added COVID-19 testing and treatments products to their offerings.

Here we will talk about two such companies, one is MyHealthChecked, which is primarily a manufacturer of fertility monitoring products. The company ventured into the COVID-19 at-home testing business due to growing demand. On the other hand, Alliance Pharma is a dividend paying specialist drugs business with global range of products.

MyHealthChecked (MHC) & Alliance (APH): market cap & one year return(Data source: EODHD/Others)

MyHealthChecked Plc (LON:MHC)

MyHealthChecked is a provider of healthcare applications and devices used to monitor fertility hormones. It has also been engaged in offering diagnostic healthcare that includes a COVID-19 at-home testing kit. In June 2021, it acquired Nell Health Ltd, a technology-led genetic-testing platform and provider of personalised nutrition solutions, for £1.2 million.

MyHealthChecked shares closed at GBX 2.40 on Wednesday, 29 September 2021.

Its revenues for the half-year period ended 30 June 2021 reached £3.27 million compared to £12,707 in H1 2020. Its cash balance as of 30 June 2021 was £2.21 million compared to £1.35 million as of 30 June 2020.

In the last one year, the shares of MyHealthChecked returned 140.00% to shareholders, and the market cap of the company stands at £18.15 million as of 29 September 2021.

Alliance Pharma Plc (LON:APH)

Alliance Pharma is a British specialty pharmaceutical firm. Alliance Pharma recorded a 24% year-on-year growth in revenue to £80.9 million for H1 2021 ended 30 June 2021. Its underlying profit before tax rose by 24% year-on-year to £20.1 million in H1 2021 compared to £16.3 million in H1 2020 and reported profit before tax of £16.5 million in H1 2021 compared to £0.6 million in H1 2020.

Alliance Pharma shares closed at GBX 104.20 on Wednesday 29 September 2021.

Alliance Pharma declared an interim dividend of 0.563 pence per share, representing an increase of 5% year-on-year from 0.536 pence per share in H1 2020.

In the last one year, the shares of Alliance Pharma returned 41.77% to shareholders, and the market cap of the company stands at £ 558.51 million as of 29 September 2021.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.